Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy.
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2015
Price : $35 *
At a glance
- Drugs Canakinumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms CanaRIa
- 07 Nov 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 25 Jul 2014 New trial record